News

  • 13 July 2011

    Sequana Medical announced today that it has received CE Mark approval for the commercial sale of its ALFApumpTM System. Over the coming months, the company will launch the product in selected hepatology and liver transplant hospitals across Europe. The ALFApump System is indicated for the management of refractory and recurrent ascites due to liver cirrhosis, a condition where massive and uncontrolled fluid accumulation occurs in the abdominal cavity.

  • 6 July 2011

    Endosense and GE Healthcare have entered into a joint development agreement to integrate the contact-force data provided by Endosense into GE’s CardioLab electrophysiology recording and Innova imaging platforms. By combining their technologies, the companies are working on the development of an all-in-one system for performing catheter ablation procedures for the treatment of cardiac arrhythmias.

  • 30 May 2011

    NovaShunt AG has launched a new corporate identity and product branding to support its goal of leadership in the area of fluid management within the body. The company will now operate as Sequana Medical AG as it prepares for the upcoming launch of the ALFApumpTM System in Europe.

  • 9 May 2011

    Santhera Pharmaceuticals (SIX: SANN) announced today that it will present first analyses of the 2-year open-label study (DELPHI-E) evaluating Catena® for the treatment of Duchenne Muscular Dystrophy. The findings indicate that Catena® can slow the decline in respiratory function associated with patients as they age. Data will be presented on May 9, 2011 in Lille, France at the 4th International Congress of Myology [1].

  • 5 May 2011

    NovaShunt AG, a private Swiss medical device company with innovative fluid management technologies, announced today that it has raised CHF 23.7 million (about $25 million) in a Series B preferred share financing round co-led by BioMedInvest AG, Entrepreneurs Fund and Capricorn Health-tech Fund. Existing investors, NeoMed and VI Partners, were also significant participants in the new financing and NeoMed retains its role as the lead investor and largest shareholder of NovaShunt.